Go Deep
Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | -17,796 | -1.1 | -1.59 | -0.10 | 625.69 |
| Oct 2026 | -17,664 | -1.1 | -1.53 | -0.10 | 601.97 |
| Oct 2026 | -17,802 | -1.1 | -1.59 | -0.10 | 624.84 |
| Oct 2026 | -17,624 | -1.1 | -1.51 | -0.10 | 593.86 |
| Oct 2026 | -17,514 | -1.1 | -1.47 | -0.10 | 576.48 |
| Oct 2026 | -17,696 | -1.1 | -1.54 | -0.10 | 606.35 |
| Oct 2026 | -17,710 | -1.1 | -1.55 | -0.10 | 607.22 |
| Oct 2026 | -17,704 | -1.1 | -1.55 | -0.10 | 605.05 |
| Oct 2026 | -17,572 | -1.1 | -1.49 | -0.10 | 585.75 |
Cartesian Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 78,000.0 | 947,000.0 | 452,000.0 |
| Net Profit | 15,769,000.0 | -39,182,000.0 | -92,576,000.0 | -35,902,000.0 |
| EPS | 0.5 | -1.5 | — | -1.4 |
Cartesian Therapeutics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 2,797,000.0 | 38,913,000.0 | 26,004,000.0 | 110,777,000.0 | — |
| Net Profit | -130,302,000.0 | -77,424,000.0 | -219,710,000.0 | 35,379,000.0 | — |
| EPS | -5.0 | -4.5 | -49.8 | 7.2 | — |
Cartesian Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 296,411,000.0 | 435,023,000.0 | 305,050,000.0 | 165,886,000.0 | — |
| Total Liabilities | 422,651,000.0 | 441,825,000.0 | 745,234,000.0 | 72,058,000.0 | — |
| Total Equity | -126,240,000.0 | -6,802,000.0 | -440,184,000.0 | 93,828,000.0 | — |
Owes vs Owns
Cartesian Therapeutics, Inc. owed $1.39 for every $1 it owned in Jun 2026, up from $0.43 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 1.39× | 1.43× | 1.02× | 2.44× | 0.43× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Cartesian Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 42.2%Fixed assets (tangible) 6.0%Intangible assets 47.9%Other assets 3.5%
How it's funded — Dec 2025
Short-term debt 1.0%Long-term debt 2.0%Other liabilities 96.7%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 125.1 | 212.6 | 76.9 | 134.6 |
| Receivables | 1.1 | 0.9 | 8.9 | 9.8 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 17.8 | 15.4 | 12.2 | 14.4 |
| Intangible assets | 142.1 | 198.8 | 198.8 | 0.0 |
| Long-term investments | 0.0 | 2.0 | 2.0 | 2.0 |
| Other assets | 10.3 | 5.3 | 6.3 | 5.1 |
| Liabilities & equity | ||||
| Short-term debt | 4.2 | 2.9 | 2.2 | 8.5 |
| Long-term debt | 8.5 | 11.1 | 8.8 | 17.8 |
| Payables | 1.3 | 0.3 | 3.1 | 0.3 |
| Other liabilities | 408.7 | 427.6 | 731.1 | 45.5 |
| Shareholders' equity | -126.2 | -6.8 | -440.2 | 93.8 |
| Net tangible assets | -268.3 | -205.6 | -638.9 | 93.8 |
Cartesian Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -73,941,000.0 | -23,674,000.0 | -51,161,000.0 | -31,631,000.0 | — |
| Investing Activities | -5,454,000.0 | -8,742,000.0 | 34,609,000.0 | -15,002,000.0 | — |
| Financing Activities | -8,055,000.0 | 168,428,000.0 | -13,145,000.0 | 39,215,000.0 | — |